Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Purpose This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). Methods One hundred and seven patients with locally advanced or metasta...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2018-06, Vol.81 (6), p.1007-1015
Main Authors: Lan, Yan-qin, Kong, Ling-jun, Lin, Xiao-yan, Xu, Qian, Gao, Xin-yan, Wu, Ri-ping, Wang, Xin-li, Zhong, Dong-ta
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adult
Aged
Anemia
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Cancer Research
Chemotherapy
Disease control
Disease-Free Survival
Fatigue
Female
Gastric cancer
Humans
Infusions, Intravenous
Intravenous administration
Lesions
Leukopenia
Male
Medicine
Medicine & Public Health
Metastases
Middle Aged
Neoplasm Metastasis
Neutropenia
Oncology
Original Article
Oxaliplatin
Oxaliplatin - administration & dosage
Paclitaxel
Paclitaxel - administration & dosage
Patients
Peripheral neuropathy
Pharmacology/Toxicology
Retrospective Studies
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Survival
Survival Rate
Toxicity
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). Methods One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous infusions of PTX at 135 mg/m 2 and OXA at 85 mg/m 2 on day 1 every 14 days. Results Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measurable lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9–52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5–87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30–7.30 months) and the median overall survival was 11.5 months (95% CI 9.08–13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients. Conclusions Combination chemotherapy with PTX and OXA offers a new, effective and safe regimen for patients with advanced gastric cancer.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-018-3576-x